Toviaz
(Fesoterodine)ApprovedSmall molecule
PfizerToviaz is a small molecule that works as a Muscarinic Acetylcholine Receptor M2 Antagonist; Muscarinic Acetylcholine Receptor M3 Antagonist.[2] It is being used across 4 indications, with its most advanced program in Approved.[1]
Toviaz is one of 35 small molecule programs targeting Neurogenic bladder. It is currently in Approved.
4
Indications
37
Total Trials
0
Active Trials
34
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Overactive Bladder
#DrugCompanyPhaseTrials
1Myrbetriq
AstellasApproved
Vesicare
AstellasApproved
Detrol La
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Flomax
SanofiApproved
Cialis
Eli LillyApproved
Enablex
AbbVieApproved
Oxytrol
WWim Janssens
Approved
Cipro
BayerApproved
Activella
Eli LillyApproved
Toviaz
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Overactive Bladder16 trials
Show 13 more trials
A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
Completed·—·Phase 4·NCT01661166·3 enrolled
Single Dose2 trials
Desmopressin1 trial
13 more indications
Autonomic Dysreflexia1 trial
Effectiveness1 trial
Cognitive impairment1 trial
Stroke1 trial
Stress urinary incontinence1 trial
Unspecified4 trials
Show 1 more trial
Regulatory
FDA Approval Timeline[4]
Oct 31, 2008
TOVIAZ
NDA NDA022030
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fesoterodine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Toviaz. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Patent Landscape[5]
Patent Cliff
Jun 7, 2027
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8088398Jun 7, 2027
7807715Jun 7, 2027
8501723Jun 7, 2027
7807715*PEDDec 7, 2027
8088398*PEDDec 7, 2027
1 more patents
8501723*PEDDec 7, 2027